Ann Dermatol.  2016 Dec;28(6):777-779. 10.5021/ad.2016.28.6.777.

Eruptive Benign Melanocytic Nevi Formation Following Adalimumab Therapy in a Patient with Crohn's Disease

• Moon IJ
• Won CH
• Lee MW
• Choi JH
• Chang SE

• KMID: 2368135
• DOI: http://doi.org/10.5021/ad.2016.28.6.777

Abstract

No abstract available.

MeSH Terms

Adalimumab*
Crohn Disease*
Humans
Nevus, Pigmented*
Adalimumab

Figure

• 

  Fig. 1 (A) Multiple melanocytic nevi scattered on the left upper arm, (B) both lower legs, and (C) on the back. (D) One of the nevi (indicated by an arrow) was biopsied, whose histologic findings are illustrated in Fig. 2.

• 

  Fig. 2 (A) Nevus cells are arranged in nests, superficially and symmetrically within the lesion (H&E, ×100). (B) Neither diffuse atypia nor other findings suggestive of malignancy is noted (H&E, ×200). Other biopsied lesions shared very similar histologic findings.

Reference

1. de Boer NK, Kuyvenhoven JP. Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn's disease patient. Inflamm Bowel Dis. 2011; 17:E26.

2. Kouklakis G, Efremidou EI, Pitiakoudis M, Liratzopoulos N, Polychronidis ACh. Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer. Drug Des Devel Ther. 2013; 7:195–199.

3. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013; 72:517–524.

4. Park JJ, Lee SC. A case of tumor necrosis factor-alpha inhibitors-induced pustular psoriasis. Ann Dermatol. 2010; 22:212–215.

5. Katoulis AC, Kanelleas A, Zambacos G, Panayiotides I, Stavrianeas NG. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology. 2010; 221:9–12.